Haukeland Universitetssjukehus

The Haukeland Universitetssjukehus research unit focuses on improving heart health by studying long‑term prevention strategies after coronary events.

• Aspirin discontinuation versus continuation in elderly patients post‑acute coronary syndrome
• Assessment of net clinical benefit using a composite endpoint of cardiovascular death, myocardial infarction, stroke and major bleeding
• Evaluation of secondary prevention measures in patients 2–8 years after an index ACS event

The trials aim to refine guidelines for chronic coronary syndrome management and reduce adverse bleeding while maintaining protection against future cardiac events.

Research at the medical department includes cutting‑edge studies on blood‑cancer therapies for patients with relapsed or refractory disease.

• Elranatamab combined with daratumumab for multiple myeloma treatment
• Comparison of novel monotherapy versus standard daratumumab‑pomalidomide‑dexamethasone regimen
• Safety monitoring for dose‑limiting toxicities and infection risk mitigation

These investigations seek to identify more effective and tolerable options for multiple myeloma patients, potentially establishing new standards of care.

The site also explores fundamental physiological processes that underpin both cardiac and pulmonary function, supporting the therapeutic trials.

• Measurement of circulatory dynamics in patients receiving antiplatelet therapy
• Respiratory monitoring during intensive chemotherapy regimens
• Analysis of hemodynamic responses to novel immunotherapy combinations

By linking physiological data with clinical outcomes, the research enhances understanding of how treatments affect overall body systems.